The purpose of the RETHINC study is to determine whether symptomatic current and former smokers with normal lung function will benefit from the use of bronchodilator therapy currently used to treat patients who have Chronic Obstructive Pulmonary Disease (COPD).
The first choice for therapy in persons with Chronic Obstructive Pulmonary Disease (COPD) is a long-acting bronchodilator. These persons have evidence of airflow obstruction on a special breathing test called “spirometry”. However, it has been unclear whether current and former smokers who have symptoms but do not have evidence of airflow obstruction on spirometry benefit from bronchodilators. Our aim is to determine whether such individuals will derive benefit from the use of bronchodilator therapy.
To find a study site near you, and/or to speak with a study representative about participating, please click on the ‘Locations’ link.
The PTC partners with the COPD Foundation to bring this clinical trial to the patients’ community. For more information on the COPD Foundation, go to: www.copdfoundation.org